In model 1 and 2 multivariate analyses, HER2 category 3 significantly increased the trend hazard ratios for tumour-related death (model 1 and model 2, P<0.001) but failed to significantly increase the trend hazard ratios for tumour recurrence (model 1, P=0.082; model 2, P=0.086). This evidence concerns the gene ERBB2 and neoplasm.